IL10 and cancer: IL-10 expression was also associated with better DFS in non-basal samples (P = 0.011), non-TN (P = 0.015), ER-positive (P = 0.039), and PgR-positive (P = 0.029) (Supplementary Fig. 2a–d, respectively) cancers but not with the basal (P = 0.980), ER-negative (P = 0.801), PgR-negative (P = 0.835), Her-2-positive (P = 0.144), Her-2-negative (P = 0.135), or TN (P = 0.760) samples.